Karyopharm Therapeutics (KPTI) Gross Margin (2019 - 2025)
Karyopharm Therapeutics (KPTI) reported Gross Margin of 96.06% for Q4 2025, up 42.0% on a YoY basis from 67.65% in Q4 2024, and up 0.83% quarter-over-quarter from 95.27% in Q3 2025.
Karyopharm Therapeutics (KPTI) Gross Margin (2019 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Gross Margin for 6 years, with the latest figure at 96.06% in Q4 2025.
- For the quarter ending Q4 2025, Gross Margin rose 42.0% year-over-year to 96.06%; the trailing twelve-month figure through Dec 2025 stood at 96.1% (up 20.0% YoY), and the FY2025 full-year result was 96.02%, up 16.0% from the prior year.
- Gross Margin for Q4 2025 stood at 96.06%, up from 95.27% in the prior quarter.
- The five-year high for Gross Margin was 99.41% in Q4 2021, with the low at 94.23% in Q1 2024.
- Historically, Gross Margin has averaged 96.49% across 5 years, with a median of 96.65% in 2024.
- The largest YoY upside for Gross Margin was 267 bps in 2022 against a maximum downside of 498 bps in 2022.
- Karyopharm Therapeutics' Gross Margin stood at 99.41% in 2021, then decreased by 5 bps to 94.44% in 2022, then climbed by 1 bps to 95.6% in 2023, then grew by 0 bps to 95.64% in 2024, then rose by 0 bps to 96.06% in 2025.
- The last three Gross Margin figures came in at 96.06% (Q4 2025), 95.27% (Q3 2025), and 97.32% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 79.04% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | 96.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 96.06% |
| Sep 30, 2025 | 95.27% |
| Jun 30, 2025 | 97.32% |
| Mar 31, 2025 | 95.82% |
| Dec 31, 2024 | 95.64% |
| Sep 30, 2024 | 96.65% |
| Jun 30, 2024 | 96.72% |
| Mar 31, 2024 | 94.23% |
| Dec 31, 2023 | 95.60% |
| Sep 30, 2023 | 97.47% |
| Jun 30, 2023 | 96.82% |
| Mar 31, 2023 | 96.51% |
| Dec 31, 2022 | 94.44% |
| Sep 30, 2022 | 97.29% |
| Jun 30, 2022 | 97.63% |
| Mar 31, 2022 | 97.01% |
| Dec 31, 2021 | 99.41% |
| Sep 30, 2021 | 98.44% |
| Jun 30, 2021 | 94.96% |
| Sep 30, 2019 | 92.30% |